ACRO Biomedical’s Bionic Innovation Featured on Prestigious International Journal Cover

 

ACRO Biomedical (Emerging Stock Code: 6748) continues to push the boundaries of regenerative medicine and explore blue ocean markets, achieving two major milestones this quarter:

 

1. Collagen ADM Scaffold has obtained FDA 510(k) clearance, allowing applications in wound care and potential hair regeneration solutions.

2. The company’s ADM-based neuromorphic device, developed by integrating collagen-based biomembranes with semiconductor technology, was featured on the cover of ACS Nano, a renowned international journal.

Renowned for its Class III medical devices and research in tissue and organ regeneration, ACRO Biomedical collaborated with Prof. Kuan-Chang Chang’s team to develop a new bioelectromechanical, human-machine, and brain-machine interface technology. This innovative breakthrough was presented at Peking University and recognized by ACS Nano for its pioneering contributions to biomedical engineering.

A Leap Forward in Bioelectronics: The ADM-Based Neuromorphic Device

Dr. Dar-Jen Hsieh, Chairman of ACRO Biomedical, emphasized that their ADM-based neuromorphic device is built with:

• Ultra-low voltage & power consumption

• Record-breaking reliability

• Peptide-free collagen biomaterial for chip fabrication

By incorporating forgetting algorithms, ACRO has successfully engineered a biocompatible brain-machine interface with seamless human integration. This marks a revolutionary step toward foreign body-free neural interfaces in medicine.

Global Innovation & Regenerative Medicine Breakthroughs

As of today, ACRO Biomedical has secured 92 patents worldwide, with over 20 additional patents under review. The company has rapidly translated its innovations into applications spanning wound care, dentistry, orthopedics, ophthalmology, and aesthetic medicine. Furthermore, ACRO is pioneering organ regeneration technologies, including heart, kidney, and liver reconstruction.

Dr. Hsieh stated that ACRO’s regenerative medicine technology is achieving a quantum leap in tissue and organ reconstruction. By leveraging Supercritical CO₂ Technology in regenerative medicine, the company has developed collagen-based natural scaffolds that serve as biological signaling environments for tissue formation and repair.

In essence, tissue and organ regeneration relies on precise cellular signaling. Without biocompatible signal integration, cellular regeneration becomes impossible—akin to losing an object in the vast ocean without a guiding light. ACRO’s ADM-based neuromorphic device addresses this challenge by utilizing nano-microstructured bioelectronic signals. These biocompatible materials, combined with neural networks, optics, and electronics, form an intelligent bioelectronic interface, enabling a deeper understanding of human physiology and paving the way for the next generation of bionic medical applications.